


IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: MOTOMIYA =1

Re Application of:)	Conf. No.: 6615
Yoshihiro MOTOMIYA et al)	
Appln. No.: 10/516,688)	Art Unit: 1632
Filing Date: June 6, 2003)	Examiner:
)	Washington, D.C.
)	August 8, 2005
For: AGENT FOR TREATMENT OF)	
METABOLIC BONE DISEASE)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s),

which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.

[X] 3. Documents AF and AH are not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states:

[X] An English translation of each document AF and AH (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.

[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

[] 5. Other information being provided for the examiner's consideration follows:


International Search Report

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:



Sheridan Neimark
Registration No. 20,520

:jaa
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202)628-5197
Facsimile: (202)737-3528

Substitute for form 1449A/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/516,688
Filing Date	June 6, 2003
First Named Inventor	Yoshihiro, MOTOMIYA et al
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	MOTOMIYA =1

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Foreign Patent Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ² Kind Code ⁵ (if known)				
	AA	EP	0 499 242 A1	08-19-1992	TAKEDA CHEMICAL INDUSTRIES, LTD.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AB	IMAZEKI, et al, ""Rapidly progressive renal failure model rat induced by adenine diet". J. Am. Soc. Nephrol. (2001). 12: A4267.	
	AC	KOEDA, et al, "Early changes of proximal tubles in the kidney of adenine-ingesting rats, with special reference to biochemical and electron microscopic studies". Japanese Journal of Nephrology. (1988). 30(3):239-246.	
	AD	MORIGUCHI, et al, "Rapidly progressive secondary hyperparathyroidism due too renal failure in rats induced by adenine diet". J. Am. Soc. Nephrol. (2001) 12: A4301.	
	AE	MUNDY, G.R., "Factors which stimulate bone growth in vivo". Growth Regulation. (1993). 3:124-128.	
	AF	OKADA, et al, "Effect of rHuEPO on bone mineral density (BMD)". Proceedings of the 9 th Congress on Kidney and Erythropoietin Study. (October 28, 2000). Tokyo. pp. 37-41.	Abs
	AG	YOKAZAWA, et al, "Animal model of adenine-induced chronic renal failure in rats". Nephron. (1986). 44:230-234.	
	AH	YOKOZAWA, et al, "Adenine-induced hyperuricemia and renal damage in rats". Nippon Nogeikagaku Kaishi (1982). 56(8):655-663.	Abs.

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.